Related Experiment Video
Updated: Jul 26, 2026
08:40
Chronic Salmonella Infection Induced Intestinal Fibrosis
Published on: September 22, 2019
IL-6 and Crohn's disease.
1Department of Molecular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan. hiroito@imed3.med.osaka-u.ac.jp
Current Drug Targets. Inflammation and Allergy
|October 17, 2003
Summary
Targeting the Interleukin-6 receptor (IL-6R) pathway shows promise for treating Crohn's disease. Blocking IL-6R with an antibody reduced intestinal inflammation and induced T-cell apoptosis in animal models.
Area of Science:
- Immunology
- Gastroenterology
- Molecular Biology
Background:
- Interleukin-6 (IL-6) is a key cytokine involved in immune regulation, inflammation, and oncogenesis.
- IL-6 exerts its effects by binding to IL-6 receptor (IL-6R), which then signals through gp130.
- Both IL-6 and soluble IL-6R (sIL-6R) levels are elevated in active Crohn's disease patients.
Purpose of the Study:
- To investigate the therapeutic potential of targeting the IL-6/IL-6R pathway in Crohn's disease.
- To evaluate the efficacy of anti-IL-6R monoclonal antibody (mAb) in preclinical models of intestinal inflammation.
Main Methods:
- Administration of anti-IL-6R mAb in animal models of intestinal inflammation.
- Assessment of inflammatory markers, adhesion molecule expression, and cytokine mRNA levels.
- Evaluation of therapeutic effects on established colitis, including T-cell apoptosis.
Main Results:
- Anti-IL-6R mAb treatment prevented intestinal inflammation and systemic wasting in animal models.
- The antibody suppressed adhesion molecule expression and reduced pro-inflammatory cytokine mRNA (TNF-alpha, IL-1beta, IFN-gamma).
- Therapeutic efficacy was observed in established colitis, mediated by lamina propria T-cell apoptosis.
Conclusions:
- Targeting the IL-6/sIL-6R pathway is a promising therapeutic strategy for Crohn's disease.
- Clinical trials of humanized anti-IL-6R mAb are underway, supporting its potential clinical application.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:26Inflammatory Bowel Disease I: Introduction
Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...